MedPath

EFFECT OF KETAMINE NEBULIZATION IN ACUTE RESPIRATORY DISTRESS SYNDROME

Phase 1
Conditions
Health Condition 1: J989- Respiratory disorder, unspecified
Registration Number
CTRI/2024/07/071197
Lead Sponsor
King George Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Age 20-50 years

Mechanically ventilated adult patients admitted to the

ICU with developing ARDS.

Exclusion Criteria

Pregnant women

Patient/Attendant not giving consent

Underlying cardiac, and neurological disorders

Previous history of psychiatric disorder / substance abuse APACHE Score =25

Patient expiring within 3 days of initiation of therapy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the therapeutic effect of ketamine nebulization in ARDS based on Murray Score.Timepoint: 28 Days
Secondary Outcome Measures
NameTimeMethod
To evaluate effect of ketamine nebulization on 28 days mortality in ARDS patientsTimepoint: 28 days;To evaluate the effect of ketamine nebulization on IL-6 levels in ARDS patients on Day 1, 3 & 5.Timepoint: 5 days
© Copyright 2025. All Rights Reserved by MedPath